316 related articles for article (PubMed ID: 25732405)
21. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
Lusthaus JA; Goldberg I
Expert Opin Drug Saf; 2017 Sep; 16(9):1071-1078. PubMed ID: 28656780
[TBL] [Abstract][Full Text] [Related]
22. A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension.
Mishra A; Agrawal M; Tripathi A; Bhirud A; Kumar LCR; Vinod K BB
J Ocul Pharmacol Ther; 2024 May; 40(4):240-245. PubMed ID: 38598266
[No Abstract] [Full Text] [Related]
23. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy.
Shin D
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S163-8. PubMed ID: 10665519
[TBL] [Abstract][Full Text] [Related]
24. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
25. 24-Hour Intraocular Pressure Control with Fixed-dose Combination Brinzolamide 1%/Brimonidine 0.2%: A Multicenter, Randomized Trial.
Weinreb RN; Bacharach J; Fechtner RD; Kahook MY; Wirta D; Burmaster S; Meng X; Hubatsch DA
Ophthalmology; 2019 Aug; 126(8):1095-1104. PubMed ID: 30403988
[TBL] [Abstract][Full Text] [Related]
26. Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.
Shoji N; Ogata H; Suyama H; Ishikawa H; Suzuki H; Morita T; Kawai H; Nishimoto H; Nemoto T; Shimizu K
Curr Med Res Opin; 2005 Apr; 21(4):503-8. PubMed ID: 15899098
[TBL] [Abstract][Full Text] [Related]
27. The 24-Hour Effects of Brinzolamide/Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure.
Seibold LK; DeWitt PE; Kroehl ME; Kahook MY
J Ocul Pharmacol Ther; 2017 Apr; 33(3):161-169. PubMed ID: 28129020
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Silver LH
Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
[TBL] [Abstract][Full Text] [Related]
29. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group.
Sall K
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S155-62. PubMed ID: 10665518
[TBL] [Abstract][Full Text] [Related]
31. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%.
Kaback M; Scoper SV; Arzeno G; James JE; Hua SY; Salem C; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2008 Oct; 115(10):1728-34, 1734.e1-2. PubMed ID: 18538406
[TBL] [Abstract][Full Text] [Related]
32. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
33. Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series.
Joh HJ; Jin SW
Jpn J Ophthalmol; 2019 Jul; 63(4):322-327. PubMed ID: 31115761
[TBL] [Abstract][Full Text] [Related]
34. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
Liu JH; Medeiros FA; Slight JR; Weinreb RN
Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
[TBL] [Abstract][Full Text] [Related]
35. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group.
Silver LH
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S147-53. PubMed ID: 10665517
[TBL] [Abstract][Full Text] [Related]
36. Comparison of dorzolamide/timolol vs brinzolamide/brimonidine fixed combination therapy in the management of primary open-angle glaucoma.
Kozobolis V; Panos GD; Konstantinidis A; Labiris G
Eur J Ophthalmol; 2017 Mar; 27(2):160-163. PubMed ID: 27445072
[TBL] [Abstract][Full Text] [Related]
37. Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries.
Rouland JF; Le Pen C; Gouveia Pinto C; Berto P; Berdeaux G
Pharmacoeconomics; 2003; 21(3):201-13. PubMed ID: 12558470
[TBL] [Abstract][Full Text] [Related]
38. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprost therapy.
Konstas AG; Holló G; Haidich AB; Mikropoulos DG; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Konidaris V; Samples JR
J Ocul Pharmacol Ther; 2013 Sep; 29(7):652-7. PubMed ID: 23550916
[TBL] [Abstract][Full Text] [Related]
39. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Day DG; Hollander DA
Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
[TBL] [Abstract][Full Text] [Related]
40. Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients.
Wang TH; Huang JY; Hung PT; Shieh JW; Chen YF
J Formos Med Assoc; 2004 May; 103(5):369-73. PubMed ID: 15216404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
